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Abstract
The epithelial cell adhesion molecule gene (EPCAM, previously known as TACSTD1 or TROP1)
encodes a membrane-bound protein that is localized to the basolateral membrane of epithelial
cells and is overexpressed in some tumors. Biallelic mutations in EPCAM cause congenital tuft-
ing enteropathy (CTE), which is a rare chronic diarrheal disorder presenting in infancy. Monoal-
lelic deletions of the 3′ end of EPCAM that silence the downstream gene,MSH2, cause a form of
Lynch syndrome, which is a cancer predisposition syndrome associated with loss of DNA mis-
match repair. Here, we report 13 novel EPCAM mutations from 17 CTE patients from two sepa-
rate centers, review EPCAMmutations associatedwith CTE and Lynch syndrome, and structurally
model pathogenic missense mutations. Statistical analyses indicate that the c.499dupC (previ-
ously reported as c.498insC) frameshift mutation was associated with more severe treatment
regimens and greater mortality in CTE, whereas the c.556-14A>G and c.491+1G>A splice site
mutations were not correlated with treatments or outcomes significantly different than random
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
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simulation. These findings suggest that genotype–phenotype correlations may be useful in con-
tributing to management decisions of CTE patients. Depending on the type and nature of EPCAM
mutation, one of two unrelated diseases may occur, CTE or Lynch syndrome.
K EYWORDS
congenital tufting enteropathy, EPCAM, genotype-phenotype correlation, in silico simulation,
Lynch syndrome, protein modeling
1 BACKGROUND
Epithelial cellular adhesion molecule (EPCAM, formerly known as TAC-
STD1 or TROP1; MIM# 185535) encodes the EpCAM protein, which
is normally expressed on the basolateral membrane of cells in epithe-
lial tissues and on plasma cells and was originally identified as a
tumor antigen (Bergsagel, Victor-Kobrin, Timblin, Trepel, & Kuehl,
1992;Herlyn, Steplewski, Herlyn, &Koprowski, 1979; Litvinov, Bakker,
Gourevitch, Velders, & Warnaar, 1994; Litvinov, Velders, Bakker,
Fleuren, & Warnaar, 1994). Mutations in EPCAM have been linked to
two distinct diseases, congenital tufting enteropathy (CTE) and Lynch
syndrome (previously calledhereditarynonpolyposis colorectal cancer
or HNPCC).
1.1 EPCAM in CTE
Biallelic inactivation of EPCAM (Sivagnanam et al., 2008) causes CTE
(MIM# 613217), which is a rare autosomal recessive diarrheal disor-
der (Reifen, Cutz, Griffiths, Ngan, & Sherman, 1994) with an estimated
incidence of one in 50,000–100,000 births based on a study in West-
ern Europe (Goulet, Salomon, Ruemmele, de Serres, & Brousse, 2007).
In addition to being caused by EPCAM mutations (Sivagnanam et al.,
2008), mutations in SPINT2 (MIM# 605124) have been implicated in
a syndromic form of the disease (Salomon et al., 2014), which may
cause an indirect loss of EpCAM protein due to proteolysis by acti-
vation of matriptase (Wu, Feng, Lu, Morimura, & Udey, 2017). CTE
presentswithin the firstmonths of lifewith severe chronicwatery diar-
rhea and growth restriction. CTE patients require rapid diagnosis and
often immediate total parenteral nutrition (TPN) therapy to sustain
adequate caloric and fluid intake, and to prevent mortality by effec-
tively bypassing the gut (Beck, Kang, & Suh, 2001; Goulet et al., 2007).
This disease most often leads to intestinal failure and lack of enteral
autonomy, although favorable outcomes have been reported in some
patients (Lemale et al., 2011). The current diagnostic criteria include
total or partial villus atrophy and crypt hyperplasia typically without
evidence of inflammation, in addition to characteristic focal epithelial
tufts composed of enterocytes with plasmamembrane rounding found
in the duodenum and jejunum (Sherman, Mitchell, & Cutz, 2004). The
focal epithelial tufts distinguish CTE from the other two congenital
enteropathies directly affecting enterocytes: (1) microvillous inclusion
disease (MIM#251850), which is caused by homozygous or compound
heterozygous mutations in MYO5B and is characterized by Periodic
Acid-Schiff positive inclusionbodies in the context ofmicrovillous atro-
phy (Cutz et al., 1989), and (2) tricho-hepato-enteric syndrome (MIM#
222470 and MIM# 614602), which is caused by homozygous or het-
erozygous mutations in TTC37 or SKIV2L and is characterized by facial
dysmorphism, hair abnormalities, intrauterine growth restriction, and
immune deficiency (Verloes et al., 1997).
1.2 EPCAM in Lynch syndrome
In contrast to the biallelic inactivation of EPCAM in CTE, monoallelic
deletions of the last exons of EPCAM give rise Lynch syndrome in
1–3% of affected families (Kovacs, Papp, Szentirmay, Otto, & Olah,
2009; Ligtenberg et al., 2009). Lynch syndrome (MIM# 120435) is an
autosomal dominant disease that predisposes patients to early onset
colorectal and endometrial cancers (Lynch et al., 2009). Lynch syn-
drome is caused by inheritance of one defective allele in a DNA mis-
match repair (MMR) gene, which is a pathway that primarily acts to
repair errors made during replication (Kolodner, 2016). Inheritance
of two defective alleles of a MMR gene, however, does not cause
Lynch syndrome but rather causes constitutional MMR deficiency
(CMMR-D also called biallelic MMR deficiency and MMR cancer syn-
drome; MIM# 276300), which is associated with blood-borne cancers,
central nervous system cancers, and colorectal tumors usually occur-
ring in the first two decades of life (Shlien et al., 2015). Remarkably,
Lynch syndrome is causedbydefects in only a fewof the genes involved
in MMR, predominantly MSH2 and MLH1, although carriers of PMS2
and MSH6 mutations also have Lynch syndrome though with a milder
phenotype than carriers ofMSH2 orMLH1 defects (Lynch et al., 2009).
Cancer predisposition in Lynch syndrome patients is due to
a secondary somatic inactivation of the functional MMR allele
(Hemminki et al., 1994). These tumors have strongmutator phenotype
and are clinical recognized by the instability of the number of copies of
microsatellite repeats (a microsatellite instability high or MSI-H phe-
notype). Lynch syndrome was traditionally suspected in patients pre-
senting with colon cancer before age 50, or a family history colon or
uterine cancer at a young age. The Amsterdam I and II criteria, and
more recently, the Bethesda and the revised Bethesda guidelines, pro-
pose to identify individuals who were likely to be mutation carriers
for Lynch syndrome (Giardiello et al., 2014). These guidelines iden-
tify individuals with colorectal cancer and endometrial cancer who
should undergo tumor testing for a MSI-H phenotype and immuno-
histochemical detection of MMR proteins, as well as testing for muta-
tions inMMRgenes (Wimmer&Etzler, 2008; Zeinalian,Hashemzadeh-
Chaleshtori, Salehi, & Emami, 2018). Once Lynch syndrome is identi-
fied, each case belongs to a family that requires genetic counseling,
DNA testing for the detected mutation, and screening for colorectal
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cancer. Colonoscopy is the mainstay of colorectal cancer surveillance,
particularly given that 70–80% of tumors are found proximal to the
splenic flexure. The average age of colorectal cancer due to Lynch syn-
drome is 45 years, thus screening colonoscopy for Lynch syndrome
patients is recommended at age 25 and repeated every 1 to 2 years.
If patients are found to have colorectal cancer, subtotal colectomy
may be necessary, given the marked frequency of synchronous and
metachronous colorectal cancers (Lynch et al., 2009).
EPCAM-associated Lynch syndrome is not due to loss of EPCAM per
se, but rather is due to monoallelic inactivation of the downstream
MSH2 gene (MIM# 609309) by methylation in the CpG island that
harbors the promoter and start site of MSH2 (Fishel et al., 1993). A
causative role for silencing MSH2 in Lynch syndrome in patients with
germline3′ deletionsofEPCAMhasbeendemonstratedby the fact that
second hits in tumors arise from somatic variants that affect the unsi-
lenced copy of MSH2 and are associated with the loss of the MSH2
protein (Eguchi et al., 2016; Huth et al., 2012; Kovacs et al., 2009;
Ligtenberg et al., 2009; Spaepen et al., 2013). Moreover, the presence
of multiple Alu sequences from the 3′ end of EPCAM to the middle of
MSH2 can lead to internal recombination events and deletions of por-
tions of MSH2 (Hitchins & Burn, 2011; Perez-Cabornero et al., 2011;
van der Klift et al., 2005). Losses of only the polyadenylation signal of
EPCAM, but not the promoter or start site of MSH2, leads to a Lynch
syndrome-MSH2 phenotype in those tissues that express EPCAM, and
may present clinically as a colon cancer-only phenotype (Lynch et al.,
2011).
In summary, depending on the type of mutations of EPCAM, biallelic
or monoallelic, two very distinct clinical phenotypes may occur.
2 BIOLOGICAL ROLE OF EPCAM
In normal tissues, human EpCAM is expressed on the surface of sim-
ple, pseudo-stratified, and transitional epithelia in various tissues of
the gastrointestinal tract, reproductive system, and respiratory tract.
EpCAMhas been implicated in a variety of important cellular functions
including cell proliferation, migration, adhesion, differentiation, and
cell signaling (Balzar et al., 1999; Litvinov et al., 1997; Trzpis,McLaugh-
lin, de Leij, & Harmsen, 2007; Tsaktanis et al., 2015; Winter et al.,
2003). EpCAM was first recognized as an antigen overexpressed on
human carcinoma cells, including tumors of the gastrointestinal sys-
tem, breast, thyroid, and kidney (Balzar, Winter, De Boer, & Litvinov,
1999). Decreased and altered EpCAM expression has been described
in ulcerative colitis patients where altered intestinal barrier function
is a major characteristic (Furth et al., 2006). EpCAM expression is
tightly regulated during embryogenesis, and spatiotemporal pattern-
ing of EpCAM has recently been shown to be important for embryonic
endodermal andmesodermal differentiation (Sarrach et al., 2018).
EpCAM has long been described as a cell adhesion molecule that
mediates cell–cell interactions through homooligomerization (Balzar
et al., 1999; Litvinov et al., 1997). In contrast, recent experiments have
not been able to demonstrate EpCAM protein oligomerization in vitro
and have not observed a role for EpCAM in the adhesion of carci-
noma cell lines (Gaber et al., 2018; Tsaktanis et al., 2015). Additionally,
EpCAMexpressionweakens cadherin-mediated cell adhesion and pro-
motes cell migration and cell invasion in a breast cancer cell line (Osta
et al., 2004;Winter et al., 2003). Thesemore recent observations have
led to the hypothesis that EpCAMrequires a ligand for oligomerization
or that EpCAM is not a cell adhesion molecule. Intriguingly, EpCAM
lacks structural similarity with other known cell adhesion molecules,
and the closely related homolog encoded by TACSTD2/TROP2 (MIM#
137290) does not mediate cell–cell interactions (Fornaro et al., 1995;
Gaber et al., 2018). Unlike EPCAM, homozygous and compound het-
erozygous mutations in the TACSTD2 gene do not have an intestinal
phenotype, but rather give rise to gelatinous drop-like corneal dystro-
phy (MIM# 204870; Ren et al., 2002; Tsujikawa et al., 1999).
In spite of the controversy regarding specific role of EpCAM in
mediating cell–cell by homooligomerization, a physical interaction
between EpCAM and Claudin-7, which is a component of tight junc-
tions, has been demonstrated (Ladwein et al., 2005; Wu et al., 2017),
and EpCAM contributes to formation of the intestinal barrier by
recruiting claudins to cell–cell junctions (Lei et al., 2012). In normal
intestines, Claudin-7 forms a stable protein complex with EpCAM,
whereas CTE-associated EPCAM mutations lead to instability of the
EpCAM–Claudin-7 interaction, decreasing its presence on the plasma
membrane (Mueller, McGeough, Pena, & Sivagnanam, 2014). In addi-
tion to the critical role EpCAM plays in maintenance of the intestinal
barrier, EpCAM has potent effects on cell proliferation and differen-
tiation (Tsaktanis et al., 2015). EpCAM appears to play a role in mor-
phogenesis and development of some tissues. In renal tissue, EpCAM
is upregulated postischemia inmurinemodels and thusmay have a role
in regeneration (Trzpis et al., 2007; Trzpis et al., 2008). In the pancreas,
EpCAM is involved in islet development (Cirulli, Ricordi, & Hayek,
1995; Vercollone, Balzar, Litvinov, Yang, & Cirulli, 2015); however, its
function during gut formation has not yet been elucidated. Despite the
ubiquity of EpCAM in various tissues, the primary symptoms of CTE
patients are due to intestinal defects and other systemic defects are
not typically reported. EpCAM's biologic role is multifaceted and fully
understanding its part in health and disease remains a topic of ongoing
investigation.
3 VARIANTS OF EPCAM IN HUMAN
DISEASE
The past decade has seen advances in our understanding of the genet-
ics of EPCAM. CTE-causing biallelic EPCAMmutations are predicted to
disrupt the expression and/or stability of the EpCAMprotein, whereas
Lynch syndrome is caused by monoallelic mutations affecting down-
streamMSH2. We present here novel CTE-causing variants of EPCAM
and review all known variants in relation to these disease processes.
3.1 Novel variants of EPCAM in CTE
To identify additional CTE-causing EPCAM variants, 17 CTE patients
were recruited from around the world to the University of California,
SanDiego (UCSD)and theUniversityofCalifornia, LosAngeles (UCLA).
Informed consent of the subjects was obtained according to the Insti-
tutional Review Board guidelines at UCSD andUCLA. Phenotypic data
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TABLE 1 Novel variants of EPCAM in CTE patients
Patient** Coding DNA Protein
Type of
mutation Zygosity Ethnicity Gender
TPN
requirement Transplant
1 c.113G>A;
c.48_68del21
p.(C38Y);
p.(A18_Q24del)
Missense;
in-frame
deletion
Compound
heterozygous
Caucasian M Full TPN No
2 c.1A>C; c.38_
62dup25
p.(M1L);
p.(A22Cfs*17)
Missense;
frameshift
Compound
heterozygous
Palestinian F Off TPN due
to limited
access
No
3 c.267G>C;
c.*118T>C
p.(Q89H); unknown
consequence
Missense;
unknown
Compound
heterozygous
English M Full TPN No
4 c.307G>A;
c.492-5T>C
p.(G103R); splicing
defect
Missense;
splicing
defect
Compound
heterozygous
English-
Italian
M Partial TPN No
5.1 c.491+1G>A;
c.556-14A>G
p.(W143_T164del)
[del exon 4];
p.(Y186_D219del*)
Splicing defect;
splicing
defect
Compound
heterozygous
Bangladeshi M Full TPN No
5.2 c.491+1G>A;
c.556-14A>G
p.(W143_T164del)
[del exon 4];
p.(Y186_D219del*)
Splicing defect;
splicing
defect
Compound
heterozygous
Bangladeshi M Full TPN No
6 c.492-1G>A;
c.491+1G>A
p.(W143_T164del)
[del exon 4];
p.(W143_T164del)
[del exon 4]
Splicing defect;
splicing
defect
Compound
heterozygous
Hispanic M Full TPN No
7 c.509_511del
TCA
p.(I170del) In-frame
deletion
Homozygous Pakistani Unknown Unknown Unknown
8 c.555+1G>C p.(A65Mfs*23) [del
exon 5]
Splicing defect Homozygous Turkish F Weaned off No
9.1 c.579delT p.(I193Mfs*17) Frameshift Homozygous Bedouin M Full TPN No
9.2 c.579delT p.(I193Mfs*17) Frameshift Homozygous Bedouin F Full TPN No
10 c.589C>T p.(Q197*) Truncation Homozygous Iraqi M Full TPN No
11.1 c.540delT;
c.491+1G>A
p.(F180Lfs*30);
p.(W143_T164del)
[del exon 4]
Frameshift;
splicing
defect
Compound
heterozygous
Unknown M Partial TPN No
11.2 c.540delT;
c.491+1G>A
p.(F180Lfs*30);
p.(W143_T164del)
[del exon 4]
Frameshift;
Splicing
defect
Compound
heterozygous
Unknown M Partial TPN No
12 c.757G>A p.(D253N) Missense Homozygous Turkish M Full TPN No
13 g.29411_34526
del5116
p.(Q24_Y142del) Deletion Homozygous Hispanic F Partial TPN No
14 c.227C>G p.(S76*) Truncation Homozygous Israeli F Full TPN No
**Siblings are annotatedwith decimals, e.g. patients 5.1 and 5.2.
were ascertained. Exons of the EPCAM gene were amplified by poly-
merase chain reaction from patient genomic DNA and subjected to
Sanger sequencing as previously described (Sivagnanam et al., 2008;
Sivagnanam et al., 2010).
Of the 17 newly identified patients, there were 11 males, five
females, and the gender of one patient was not obtained. The disease
outcomes included: 10 patients treated with full TPN, four patients
treated with partial TPN, and two patients weaned off TPN (one due
to limited vascular access); the treatment of one patient was unknown.
No patients underwent bowel transplantation or were deceased. Nine
patients were compound heterozygotes and eight were homozygotes
for mutations in EPCAM (Table 1).
A total of 19 distinct EPCAM mutations were observed,
and 13 of these mutations have not been previously reported
(c.1A>C, c.113G>A, c.227C>G, c.267G>C, c.589C>T, c.757G>A,
c.540delT, c.579delT, c.38_62dup25, c.48_68del21, c.509_511delTCA,
c.492-5T>C [NC_000002.12:g.47377009T>C], c.*118T>C, and a
deletion spanning the end of exon 1 and intron 3–4, NG_012352.2:
g.29411_34526del5116, which generates p.Q24_Y142del; note that
coding mutations are reported relative to the EPCAM reference
sequence NM_002354.2). None of the novel EPCAM mutations
were observed more than once outside of individual families or in
homozygous patients. This pattern is consistent with CTE affecting
children of families that carry rare recessive EPCAM mutations and
does not provide evidence for a founder effect in these patient cohorts,
unlike that observed in some patients of Kuwaiti and Middle Eastern
origin (Salomon et al., 2011).
3.2 Reported variants in EPCAM in CTE
An analysis of the 72 previously reported CTE patients (AlMahamed
&Hammo, 2017; Al-Mayouf, Alswaied, Alkuraya, AlMehaidib, & Faqih,
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F IGURE 1 Quantitative distribution of EPCAMmutations identified in CTE patients. Each patient is represented by a single box. Gray boxes
correspond to the presence of themutation in homozygous patients, whereas white boxes correspond to the presence of amutation in
heterozygous patients
2009; Bodian et al., 2017; d'Apolito et al., 2016; Ko et al., 2010; Pêgas
et al., 2014; Salomon et al., 2011; Salomon et al., 2014; Schnell et al.,
2013; Shakhnovich, Dinwiddie, Hildreth, Attard, & Kingsmore, 2017;
Sivagnanam et al., 2008; Sivagnanam et al., 2010; Tang, Huang, Xu,
& Huang, 2018; Thoeni et al., 2014) along with the 17 novel patients
reported here is consistent with the expected genetics of an auto-
somal recessive disease (Figure 1; Supporting Information Table 1).
Many CTE patients (60 of 90 patients) were homozygous for EPCAM
mutations, and most of the remainder were compound heterozygotes
(24 of 90 patients). The large proportion of homozygote individuals is
consistent with the high incidence of CTE patients amongst consan-
guineous families (21 of the 30 cases where information was available)
and/or were consistent with founder effects, as has been previously
reported (Salomon et al., 2011). Additionally, for the 88 patientswhere
gender was known (50 males and 38 females), there was no bias (P =
0.36, chi-squared test). The majority of patients are Middle Eastern in
descent, though several other ethnicities were represented, including
Caucasian andHispanic.
The 90 reported CTE patients implicate 42 distinct EPCAM muta-
tions in causing CTE (Figures 2a and 2b). These mutations include
six chromosomal deletions, eight noncoding/splicing mutations, 16
frameshifts/nonsense mutations that would lead to EpCAM trun-
cation, and 12 missense mutations or in-frame deletions. Only four
mutations have been reported in five or more patients: c.499dupC
(previously reported as c.498insC; 28 patients, 23 homozygotes),
c.556-14A>G (14 patients, six homozygotes), c.491+1G>A (nine
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F IGURE 2 Reportedmutations in EPCAM identified in CTE patients. (a) Reportedmutations are shown based on their effect on the gene (top),
mRNA (middle), or protein (bottom). (b) The positions of missensemutations are depicted on the EPCAMdimer structure; theoretical membrane
and transmembrane helix structures are shown to indicate protein orientation
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patients, two homozygotes), and c.492-2A>G (seven patients, two
homozygotes).
3.3 Reported variants of EPCAM in Lynch syndrome
The EPCAM gene is 17 kb upstream of the MSH2 gene on the short
arm of human chromosome 2. The first evidence that large deletions
upstream of the MSH2 gene could give rise to Lynch syndrome was
reported in families from Swiss and American populations (van der
Klift et al., 2005). Around the same time, heritable hypermethylation
of the MSH2 promoter, which was the highest in colonic mucosa and
colon tumors but lowest in blood leukocytes, was reported (Chan et al.,
2006). These two observations turned out to be linked, as monoallelic
deletions of the 3′ end of the EPCAM gene in which the polyadenyla-
tion signal is lost give rise toMSH2 promoter hypermethylation, read-
through transcriptionof theEPCAM andMSH2 genes, and loss ofMSH2
protein expression (Kovacs et al., 2009; Ligtenberg et al., 2009). As
these 3′ EPCAM deletions are germline variants, the promoter methy-
lation is heritable and has been termed an “epimutation,” which has
also been associated with the MLH1 promoter in at least one case of
Lynch syndrome (Gazzoli, Loda, Garber, Syngal, & Kolodner, 2002). In
some of the observed EPCAM-MSH2 fusion transcripts, a cryptic exon
in the intergenic region between EPCAM andMSH2was present in the
transcript (Gazzoli et al., 2002; Kovacs et al., 2009; Ligtenberg et al.,
2009).
Twenty-five 3′ deletions of EPCAM characterized at the sequence
level have been implicated in causing Lynch syndrome (Dymerska
et al., 2017; Eguchi et al., 2016; Guarinos et al., 2010; Huth et al.,
2012; Kempers et al., 2011; Kovacs et al., 2009; Kuiper et al., 2011;
Ligtenberg et al., 2009; Lynch et al., 2011; Mur et al., 2014; Nagasaka
et al., 2010; Niessen et al., 2009; Perez-Cabornero et al., 2011; Rossi
et al., 2017; Rumilla et al., 2011; Spaepen et al., 2013; van der Klift
et al., 2005). Most of these deletions are mediated by recombination
between imperfectly homologous Alu repeats (Figure 3a), which are a
class of short repeats (∼300 bp) present in >106 copies in the human
genome (Deininger, 2011). The length of the microhomologies at the
breakpoint junction has been emphasized previously (Kuiper et al.,
2011; van der Klift et al., 2005); however, even the shorter microho-
mology junctions are in the context of the larger Alu repeat homology
(Figure 3a). Consistent with this, Alu sequences on the + strand only
recombine with other Alu sequences on + strand, and the same is true
for Alu sequences on the – strand.
Twenty-three of the characterized deletions span EPCAM exons 8
and 9 (Figure 3b; Supporting Information Table 2), which eliminates
the 3′ polyadenylation signal and thereby leads to read-through
transcription of MSH2 and hypermethylation of the MSH2 promoter.
The majority of the deletions only span exons 8 and 9 (Figure 3b),
which includes the founder mutation in the Dutch population, EPCAM
c.859-1452_*1999del, (Ligtenberg et al., 2009; Lynch et al., 2011),
a potential founder mutation in the Spanish population, EPCAM
c.858+2568_*4596del (Guarinos et al., 2010; Mur et al., 2014),
and a potential founder mutation in the Polish population, EPCAM
c.858+2478_*4507del (Dymerska et al., 2017). In principal, only dele-
tion of exon 9 is required to give rise to read-through transcription of
MSH2; however, no Alu repeats are present within intron 8 (Figure 3b),
suggesting that the common codeletion of exons 8 and 9 is influenced
not by a requirement for loss of exon 8 but by the genomic context
that leads to Alu–Alu recombination events. In addition to deletions
that only affect the 3′ end of EPCAM, two deletions spanning the
3′ end of EPCAM and the 5′ end of MSH2 have also been identified
(Perez-Cabornero et al., 2011; Sekine et al., 2017).
In addition to the disease-causing variants reported here,
some nonpathogenic variants have been reported in the HGMD
(http://www.hgmd.cf.ac.uk/ac/gene.php?gene=EPCAM) and Leiden
Open Variant Database (LOVD) and are summarized in Supp. Table 3.
4 VARIANT DATABASE
A locus-specific database in the LOVD for EpCAMwas created in 2009
and is moderated by Joh Paul Plazzer, Johan den Dunnen, andMamata
Sivagnanam (https://databases.lovd.nl/shared/variants/EPCAM). All
previously published and novel mutations were recorded after per-
forming a literature search for patients with CTE or Lynch syndrome
in whom a variant in the EPCAM gene was reported. EPCAM genotypes
were recorded from the original publications when data were avail-
able. Adjustment of nomenclature of certain variations were made to
ascertain that base pair and protein sequence numbering were based
on the EPCAM reference sequence NM_002354.2.
5 EPCAM STRUCTURE AND FUNCTION
Thenine exons of the EPCAM gene encode a314 amino acid transmem-
brane glycoprotein (Figure 2a). The extracellular portion of EpCAM
and the signal peptide is encoded by exons 1 to 6 and is composed of
an N-terminal disulfide-stabilized domain, a central thyroglobulin-like
domain, and a C-terminal domain (Pavsic, Guncar, Djinovic-Carugo, &
Lenarcic, 2014). The N-terminal disulfide-stabilized domain has pre-
viously been described as an “EGF-like” domain, as the domain was
predicted to contain beta-strands and disulfides; however, the struc-
ture reveals that it has a disulfide bonding pattern more similar to
the Cripto/Fri-1/Cryptic domain of mouse Cripto and a fold more sim-
ilar to WW domains, which was named due to two conserved tryp-
tophan residues (Pavsic et al., 2014). We therefore term this domain
the N-terminal domain in this review, consistent with the terminol-
ogy in the report of the EpCAM crystal structure (Pavsic et al., 2014).
The thyroglobulin-like domain has also been referred to as a second
“EGF-like” domain; however, the similarity with thyroglobulin was rec-
ognized some time ago and verified by the EpCAMstructure (Baeuerle
&Gires, 2007;Pavsic et al., 2014). The transmembraneportion is coded
byexon7, and the intracellular domain is encodedbyexons8and9 (last
13 amino acids; Balzar et al., 1999).
5.1 Predicted structural effects of EPCAM variants
in CTE
In general, the EPCAM mutations found in CTE patients appear to
be broadly inactivating. The large chromosomal truncations (6 of
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F IGURE 3 3′ deletions of EPCAMassociated with Lynch syndrome. (a) Illustration of the homologies of two Alu–Alu recombination events
causing deletions of EPCAM exons 8 and 9. The top and bottom sequences correspond to the two Alu sequences involved in the recombination
event, and themiddle sequence is the novel junction. The sequences between the colons correspond to the identical microhomology at the
deletion junction. (b) Diagram of the EPCAM deletions. Exons 1–9 of EPCAM and the first four exons ofMSH2 are depicted at the top. Deletions are
shown in themiddle as thick black lines. The Alu repeats involved at the homology-mediated rearrangements for each deletion are shown as
labeled black boxes; black boxes above the deletion line are Alu sequences encoded on the+ strand, whereas black boxes below the deletion line
are Alu sequences encoded on the – strand. Repetitive elements on the+ and – strand identified by RepeatMasker version 406 (Smit, 2013–2015)
with the Repeat Library Version 20150807 are shown at bottom. Alu-related sequences are shown as grey and black boxes; other repeats are
shown as white boxes. Note that some deletions have previously been reported under different annotations: c.426-544_*3904del
(c.423-545_*3903del), c.555+402_*1220del (AC079775.6:g.72468_82822del10355), c.555+927_*14226del (c.555+894_*14194del),
c.858+1211_*4529del (c.85811211_4529del), c.858+1358_*4793del_insAG (c.858+1364_*4793del_insAG), c.858+2478_*4507del
(AC079775.6:g.77436_86109del8674), c.859-2524_*10762del (AC079775.6:g.77631_92364del14734), c.859-1605_*5826del
(c.859-1605_*5862del), c.859-696_*3914del (AC079775.6:g.79459_85516del6058), c.859-692_*1990del (c.859-672_*2170del),
c.859-689_*14697del (AC079775.6:g.79465_96299del16834), and c.859-645_*10911del (AC079775.6:g.79509_92513del13004). In addition,
two deletions reported as annotations but not with sequence do not support the reported junctionmicrohomologies: c.492-509_*13721del and
c.858-353_*618del
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41 mutations) give rise to variants that primarily lack most of the
N-terminal extracellular region of EpCAM, whereas the frameshift
and nonsense mutations (15 of 41 mutations) truncate the EpCAM
prior to the transmembrane helix and C-terminal intracellular region
(Pavsic et al., 2014). A small number of mutations were short (<30 bp)
duplications or deletions (four of 41) or larger chromosomal dele-
tions (six of 41). Three of these are in-frame deletions: c.48_68del21
(p.A18_Q24del) disrupts the leader peptide targeting EpCAM to the
plasma membrane; the c.509_511delTCA deletes I170, which forms
part of the hydrophobic core of the C-terminal domain; and the exon
1–4 fusion deletes the N-terminal and thyroglobulin domains. In con-
trast, the majority of point mutations (31 of 41) were single base
insertions, deletions, or changes, and most of these (21 of 31) gave
rise to frameshifts, stop codons, or splicing defects. The impact of the
observed mutations on the EpCAM protein has not yet been exten-
sively studied, althoughc.491+1G>AgeneratesmRNAmolecules lack-
ing exon 4 and c.492-2A>G causes abnormal in-frame skipping of exon
five (Salomon et al., 2011; Sivagnanam et al., 2008).
Because the CTE-associated deletion, frameshift, and splice site
mutations in EPCAM appear to be loss of functionmutations, we aimed
to understand how the known amino acid substitutionmutations could
affect the EpCAM protein structure, as most of these have not been
investigated experimentally. The nine EPCAM missense mutations
encode single amino acid substitutions primarily affected the extra-
cellular thyroglobulin homology domain and internal portions of the
extracellular C-terminal domain of EpCAM (Figures 2a and 2b), consis-
tentwith the hypothesis that defects in cell–cell interactions are causal
in CTE. Several of the amino acid substitutions are poised to disrupt
the disulfide bonding in EpCAM extracellular domains (Figure 2b). The
c.113G>A (p.C38Y) and c.197G>A (p.C66Y) mutations eliminate cys-
teine residues involveddirectly at the disulfide bonds in theN-terminal
domain and the thyroglobulin homology domain (Figures 4a and 4b).
Additionally, the c.314T>G (p.F105C) mutation provides a competing
cysteine that could isomerize the C66–C99 disulfide bond (Figure 4a).
The c.307G>A (p.G103R) mutation amino acid substitution is posi-
tioned to sterically disrupt theC66–C99disulfide bond formation (Fig-
ure4a).Other aminoacid substitutions arepositioned to locally disrupt
aspects of the EpCAM structure: the c.437T>A (p.I146N) mutation
places a polar residue in a highly hydrophobic environment (Figure 4c),
the c.359A>T (p.N120I) and c.757G>A (p.D253N) mutations affect
residues that are at one of the two contact regions between the thy-
roglobulin homology domain and the C-terminal domain (Figure 4d),
and the c.380C>T (p.T127I) mutation places a hydrophobic residue in
a polar environment and would, at a minimum, disrupt the hydrogen
bonding interactions maintained by the amino acid side chains in the
wild-type protein (Figure 4e).
5.2 Predicted structural effects of EPCAM variants
in Lynch syndrome
Most of the Lynch syndrome associated 3′ deletions of EPCAM involve
deletionsof exon8and9.Basedon theEpCAMprotein structure, these
deletions would be predicted to give rise to loss of intracellular por-
tions of EpCAM while leaving the extracellular domains and most of
the transmembrane domain intact (Figure 2a). However, it is unclear
if these truncated EpCAM proteins are made, as read-through tran-
scription would also give rise to EPCAM-MSH2 fusions (often between
EPCAM exon 7 and MSH2 exon 2, although an EPCAM exon 5-MSH2
exon 2 fusion was observed with c.555+927_*14226del and c.556-
531_*872del) and EPCAM-cryptic exon-MSH2 fusions (Eguchi et al.,
2016; Kovacs et al., 2009; Ligtenberg et al., 2009; Perez-Cabornero
et al., 2011; Spaepen et al., 2013). Most of the EPCAM exon 7-MSH2
exon 2 fusions and EPCAM exon 7-cryptic exon-MSH2 exon 2 fusions
lead to a premature stop in MSH2 exon 2, likely leading to loss of the
mRNA through nonsense-mediated decay (Maquat, 2004). In contrast,
some transcripts isolated from the c.859-696_*3914del background
involve an alternative splice site donor in EPCAM exon 7 and alterna-
tive splice site acceptors in MSH2 exon 2, and at least one transcript
leads to an in-frame fusion (Kovacs et al., 2009). In the case of one
deletion spanning EPCAM exons 6–9 andMSH2 exons 1–2, a mislocal-
ized cytoplasmic MSH2 protein was detected by immunohistochem-
istry (Sekine et al., 2017). Consistent with the possibility that many
3′ deletions of EPCAM do not produce truncated EpCAM proteins,
tumors arising in EPCAM-associated Lynch syndrome patients with a
secondary loss of thewild-type copy of EPCAM do not express EpCAM,
as observed by immunohistochemistry (Huth et al., 2012; Kang et al.,
2015; Kloor et al., 2011; Musulen et al., 2013). This study, however,
does not confirm that loss of only exons 8 and 9 of EPCAM is inacti-
vating, as the deletions were not mapped and the multiplex ligation-
dependentprobeamplification (MLPA)protocol performedonly tested
exons 3, 8, and 9 of EPCAM for copy number changes. In contrast, a
number of the larger 3′ deletions of EPCAM associatedwith Lynch syn-
drome (Figure 3b) would give rise to EpCAM truncations that overlap
with those observed in CTE and hence can be reliably predicted to be
inactivating.
Structural effects of EPCAMvariants are diverse in nature and lead
to the unique phenotypes of CTE versus Lynch syndrome.
6 ANIMAL MODELS
EpCAM is highly conserved in mammals (Balzar et al., 1999; Bergsagel
et al., 1992). The pattern of murine EpcammRNA expression is similar
to that of human EPCAM, with highest expression in the gut and lower
levels in the kidneys, pancreas, mammary glands, thyroid, pituitary,
salivary glands, lungs, and genitalia, consistent with its epithelial distri-
bution (Nagao et al., 2009). EpCAMprotein has also been identified on
the surface ofmouse embryonic, neonatal, and adult germ cells, as well
as embryonic stem cells (Basak et al., 1998; Gonzalez, Denzel, Mack,
Conrad,&Gires, 2009). In vivo roles forEpCAMhavebeen investigated
in two zebrafish knockout models, which demonstrated its function in
epithelial morphogenesis and skin development (Slanchev et al., 2009;
Villablanca et al., 2006).Epcamknockoutwas initially reported to cause
embryonic lethality inmice (Nagao et al., 2009); however, three groups
have reported viable Epcam knockouts (Gaiser et al. 2012; Guerra
et al., 2012; Lei et al., 2012). Constitutive deletion of Epcam exons 2
and 3 caused intestinal defects and an inability of the mutant mice to
gain weight and was associated with a failure to form functional tight
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F IGURE 4 Detailed views of the positions of reportedmissensemutations in EPCAM and c.491+1G>A. (a) The F105C andG103R amino acid
substitutions are positioned to affect the C66–C99 disulfide bond through disulfide bond isomerization (F105C) or through steric interactions
(G103R) as shown by themolecular surface of the argininemutant that clashes with Y32. (b) The C38Y amino acid substitution disrupts one of the
disulfides in the N-terminal domain. (c) The I146N amino acid substitution places a polar residue within the hydrophobic core of the C-terminal
domain. (d) The N120I andD253N substitutions disrupt the side chain–main chain hydrogen bonds between the thyroglobulin-like domain and
the C-terminal domain. (e) The T127I amino acid substitution would disrupt side chain–main chain interactions adjacent to the C118-C135 sulfide
bond in the thyroglobulin-like domain. (f). The c.491+1G>A splice site mutation that causes exon 4 skipping would delete a core region (red
cartoon) of the C-terminal domain
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junctions and defects in the recruitment of claudins in line with
EpCAM's role of recruiting claudins to tight junctions in cellular mod-
els (Lei et al., 2012; Wu, Mannan, Lu, & Udey, 2013). Another viable
knockout constructed by gene trapping revealed severe hemorrhagic
enteropathy (Guerra et al., 2012). EpCAM mice models with neonatal
intestinal abnormalities have suggested EpCAM affects cell–cell
junctions through expression and localization of E-cadherin and
beta-catenin, which are essential components of adherens junctions
(Guerra et al., 2012), and decreased expression of tight junction
proteins, increased permeability, and decreased ion transport in the
intestines (Kozan et al., 2015). Additionally, a conditional knockout
of Epcam in Langerhans cells demonstrated a role for EpCAM in
promoting the motility and migration of these cells from the skin to
the lymph nodes after activation (Gaiser et al., 2012). Constitutive
and inducible CTE-associated murine models express mutant EpCAM,
lacking exon 4, rather than a gene knockout, and mimic CTE with
growth retardation, and intestinal epithelial tufts. These models show
enhanced intestinal permeability and migration as well as decreased
ion transport and expression of tight junctional proteins (Kozan et al.,
2015;Mueller et al., 2014).
7 GENOTYPE–PHENOTYPE CORRELATION
The dramatically different phenotypes of CTE and Lynch syndrome
provide a clear genotype–phenotype correlation: monoallelic 3′ dele-
tion of EPCAM leading to loss of MSH2 expression does not cause
CTE, but does give rise to Lynch syndrome, whereas biallelic inactiva-
tion of EPCAM gives rise to CTE. As CTE is caused directly by loss-of-
function EPCAM mutations, a large number of inactivating mutations
can cause CTE without affecting expression of MSH2 and hence do
not cause Lynch syndrome or CMMR-D. In principle, genotypes can be
envisioned that combine both CTE and MMR defects. A combination
of Lynch syndrome and CTE could theoretically arise in a heterozy-
gote possessing a 3′ deletion of EPCAM that inactivates MSH2 and
another EPCAM inactivating mutation that does not inactivate MSH2.
A combination of CMMR-D and CTE could arise by germline biallelic
inactivation of EPCAM via 3′ deletions that also lead to loss of MSH2
expression. To date, no patient has been described with both CTE and
Lynch syndrome or CMMR-D, whichmay be due in part to the fact that
Lynch syndrome is observed at an age past the typical lifespan of CTE
patients. However, a 9-year-old patient with a heterozygous deletion
of EPCAM and a heterozygousMSH2missensemutationwas identified
as having atypical CMMR-D in which MSH2 was absent in an EpCAM
expression-dependentmanner (Li-Chang et al., 2013). This patientwas
not reported to have CTE, likely due to EpCAM expression from the
normal allele.
7.1 Genotype–phenotype correlations in CTE
A wide range of alimentary needs were noted among the 68 reported
CTE patients for whom nutritional data were available (Figure 5): four
patients were weaned off TPN entirely; 16 patients had partial TPN
ranging from 3 out of 7 (3/7) days to 6/7 days; and 48 patients were
on full TPN (7/7 days). About one-third of patients showed significant
morbidity and mortality as 13 patients underwent transplant and 12
patients were deceased. Of the transplanted patients, four patients
were deceased. We hypothesized these differential clinical outcomes,
nutritional data/TPN status, need for bowel transplantation, and
mortality, could be used as surrogate markers for disease severity. To
examine these data for evidence of a genotype–phenotype correlation,
patients were divided into genotypic groups in which EPCAM alleles
were mapped to categories (frameshift mutation, nonsense mutation,
missense mutation, and splicing defect). The nutritional requirements,
need for bowel transplantation, and mortality for each genotypic
group were then compared to the rest of the patients using the
maximum likelihood G-test (Supporting Information Table 3), which
is more appropriate than the chi-squared test for small sample sizes
(Sokal, 1994). The only genotypic group with significant differences
after multiple-test correction with a false discovery rate of 0.05 was
the frameshift/frameshift genotypic group; these patients were more
likely to require full TPN (16 of 16 patients; uncorrected P-value
0.000347; G-test) and be deceased (eight of 16 patients; uncorrected
P-value 0.000473; G-test). Thus, these patients are associated with
worse clinical outcomes and potentially more severe disease.
The small number of characterized patients and the presence of rel-
atively large numbers of compound heterozygotes complicate the use
of statistical tests like the G-test and chi-squared test for correlating
individual mutations with disease severity. We therefore performed
random (Monte Carlo) permutation tests in silico to look for individ-
ual classes of mutations (frameshift, nonsense, missense, and splice
defect) in genotypes associated with the surrogate markers of dis-
ease severity. These analyses assume that mutations that would cause
more severe disease in homozygote patients will tend to be somewhat
moredeleterious in compoundheterozygotes and thatmutations caus-
ing less severe disease will also influence severity in compound het-
erozygotes. In each trial of this simulation, the 68 nutritional (weaned,
partial TPN, or full TPN), transplant (yes or no), and mortality (yes or
no) outcomes were randomly distributed among the 68 patient geno-
types. In other words, the clinical outcomes were randomly permuted
in each round; permutation tests are useful nonparametric methods
of hypothesis testing when null hypotheses are difficult or impossible
to obtain (Fisher, 1935; Pitman, 1937; Pitman, 1938). These random
trials were run 10 million times. For each nutritional, transplant, and
mortality outcome, a distribution of the number of times the muta-
tion of interestwas associatedwith the outcomewas generated. These
distributions are null distributions that assumed the clinical outcomes
were independent of the mutations in the genotypes. These null dis-
tributions were then compared to the number of associations of clini-
cal outcomes tomutations in the real data. P-valueswere calculated by
summing the probabilities of all events in the random distribution that
were equal to or more extreme than the number of associations in the
real data. This simulation strategy accounted for the relative frequen-
cies of the mutations as well as the nonrandom cooccurrence of muta-
tions in the observed patient genotypes. Consistentwith the statistical
test results for the frameshift/frameshift genotypes, frameshift muta-
tions were more frequently present in genotypes of patients requir-
ing full TPN than predicted by chance (P = 0.003; Figure 6a) and were
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F IGURE 5 Quantitative distribution genotypes in the current literature. Colors denote current treatment status or clinical outcome of patients
with the indicated genotype; each patient is represented by a single box. Transplanted patients whowere deceased are reported as transplanted
less frequent in genotypes of patients with partial TPN (P = 0.02;
Figure 6a). Frameshift mutations were also more commonly present
in patients who were deceased (P = 0.002; Figure 6a). In contrast,
splice site mutations were less commonly present in patients requir-
ing full TPN than predicted by chance (P = 0.007): more commonly
present in patients with partial TPN (P = 0.03; Figure 6a). Neither
nonsense mutations nor missense mutations had a statistically signif-
icant association with any clinical outcome (Supporting Information
Figure 1).
We then used this Monte Carlo simulation strategy to analyze indi-
vidual mutations. The c.499dupC mutation is present in 13 of the 69
patients for which severity information was available. All 13 patients
with c.499dupC were treated with full TPN, which is significantly
more TPN treatment relative to the random simulation (P = 0.006)
and is significantly less partial TPN relative to the random simulation
(P = 0.019; Figure 6b). Additionally, the c.499dupC mutation has a
significant increase in association with mortality relative to the ran-
dom simulation (eight of the 13 patients were deceased; P = 0.0006).
No significant differences were observed for weaning from full TPN
(P=0.41) or bowel transplantation (P=0.13) relative to the simulation.
Taken together, these data suggest that the c.499dupC is correlated
withmore aggressive treatment and poorer outcomes, consistent with
more severe disease. The c.499dupC frameshift mutation is responsi-
ble for the effect of the frameshift class of mutations in the simulation
(Figure 6a) aswell as the correlation of frameshift/frameshift genotype
with more severe clinical outcomes (10 of 16 frameshift/frameshift
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F IGURE 6 Computer simulation of patient treatment/outcomes suggests a correlation between c.499dupC andmore severe disease. (a) The
number of times a category of mutation was associated with a particular treatment or outcome (vertical arrow) was compared to the expected
distribution based on random simulations (grey bars). Reported P-values are derived from the expected distributions. Statistically significant
P-values are in bold. (b) Analysis of individual mutations using random simulation as in panel A. Of the threemutations that could be analyzed, only
the c.499dupCmutation had an observed count that was statistically different than the random distribution
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genotypes are homozygous c.499dupC mutations; Supporting Infor-
mation Table 3). In contrast, the c.556-14A>G mutation (present in
14 of the 69 patients) is not correlated with treatments or outcomes
that are significantly different than randomsimulation for full TPN (P=
0.09), partial TPN (P = 0.31), weaning (P = 0.14), transplant (P = 0.81),
ormortality (P=0.63) (Figure 6b). Similarly, the c.491+1G>Amutation
(present in nine of the 69 patients) is also not correlated with signifi-
cant changes relative to the random simulation for full TPN (P = 0.08),
partial TPN (P=0.03),weaning (P=0.55), transplant (P=0.31), ormor-
tality (P = 0.36) (Figure 6b). Despite the evidence for frameshift muta-
tions in general, and c.499dupC in specific as being associated with
more severe clinical outcomes, establishing clear genotype/phenotype
correlations in CTE is complicated by several factors. These factors
including the rare occurrence of CTE, the fact that the mutations are
often present in compound heterozygotes, and the lack of standard
quantitative measures for disease severity. Use of clinical treatment,
nutritional status, and outcomes to characterize disease is also con-
founded by the individual circumstances of the patient as well as the
resources, experiences, and biases of the treatment centers. The lim-
itations of these analyses argue that the development of a quantita-
tivemeasure for CTE severity will be necessary to establish genotype–
phenotype correlations and inform patient treatment and prognosis.
7.2 Genotype–phenotype correlations
in Lynch syndrome
In EPCAM-associated Lynch syndrome, epigenetic silencing ofMSH2 is
tissue specific, giving rise to mosaic inactivation ofMSH2, the high risk
of colorectal cancer, and the low risk of endometrial cancer (Dymerska
et al., 2017; Kempers et al., 2011; Lynch et al., 2011; Perez-Cabornero
et al., 2011). In contrast, deletions that span both EPCAM and MSH2
or span regions close to the MSH2 promoter give rise to high risk for
both colorectal and endometrial cancers like mutations inMSH2 alone
(Kempers et al., 2011).
8 FUTURE PROSPECTS
EPCAM is involved in different ways in three clinically relevant
diseases.
8.1 Congenital tufting enteropathy
The fact that CTE appears to be a disease caused by relative loss-
of-function mutations places constraints on the strategies that can
be adopted for long-term therapy that weans patients from TPN. If
EpCAM functioned to suppress another competing mechanism, then
pharmacological intervention of the competing mechanism could
be pursued, such as use of matriptase inhibitors in the proposed
SPINT2/matriptase mechanism (Wu et al., 2017). Bowel transplant
has been used successfully (Paramesh et al., 2003); however, trans-
plants are complicated by the availability of donors, the need to
prevent transplant rejection, and the high rate of posttransplantation
mortality. Though technology is still evolving, intestinal stem cell
transplantation may be the next generation of transplant strategy for
CTE and other monogenic intestinal failure (Hong, Dunn, Stelzner, &
Martin, 2017). Mutations affecting EpCAM mRNA splicing are rela-
tively common in the population. Some strategies for restoration of
aberrant splicing inDuchennemuscular dystrophy and spinalmuscular
atrophy (Benchaouir, Robin, &Goyenvalle, 2015; Hua et al., 2010; Hua,
Vickers, Okunola, Bennett, & Krainer, 2008; Kole, Krainer, & Altman,
2012;Wu et al., 2017) might be applicable in a subset of CTE patients.
A more broadly useful strategy may be to use gene therapy to correct
the single nucleotide insertion, deletions, and changes that dominate
the CTE patient population. In this regard, the fact that gene therapy
may only need to act on cells in the intestinal epithelium may prove to
beanadvantage; however, it remains anopenquestion as to the level of
gene correction that would be required to ameliorate CTE symptoms.
Even in the absence ofmolecular therapies for CTE, amore pressing
concern is the timely diagnosis of infants in order to initiate appropri-
ate treatments as soon as possible. The difficult and lengthy process
of histological diagnosis, often requiring repeated endoscopies, is less
than ideal. Despite recent immunohistochemical staining advances,
including gastric and colonic biopsies when small bowel biopsies are
inconclusive, the accuracy and speed remain a limitation of this diag-
nostic modality (Ranganathan, Schmitt, & Sindhi, 2014; Treetipsatit &
Hazard, 2014). Conversely, modern genetic analyses have the promise
of accelerating the diagnostic pathway and distinguishingCTEpatients
from those suffering fromother congenital enteropathies (Thiagarajah
et al., 2018).
Modern genetic testing methodologies have the advantage of
rapidly identifying known mutations and will be particularly useful
for the commonly observed mutations. However, the fact that 13
novel mutations were identified in 17 sequenced patients, many of
whom were from families without consanguinity, argues that relying
solely on previously identified EPCAM mutations for diagnosis could
lead to many false negatives. Thus, genetic strategies should focus
on sequencing of the EPCAM gene, potentially using modern short-
read DNA sequencing combined with exon-capture technologies, and
analysis of exon copy number to identify deletions, potentially using
read depth from DNA sequencing, microarray comparative genomic
hybridization, or MLPA (Gibriel & Adel, 2017). One advantage of this
strategy is that any source of high quality genomic DNA, such as blood,
can be used for the analysis. We are hopeful that with continued vig-
ilance in sequencing patients and reporting mutations and associated
treatment regimens, genotyping will not only diagnose CTE but also
provide physicians the ability to better inform families for diagnosis,
family planning, and ultimately cater specific treatment regimens.
8.2 Lynch syndrome
Usually, EPCAM-associated Lynch syndrome is treated as classic Lynch
syndrome with aggressive colorectal cancer surveillance, genetic
counseling, and assessment of first-degree relatives. As described
above,most EPCAM-associated Lynch syndromemutations have a high
risk of colorectal cancer and a low risk of endometrial cancer unless
theMSH2 gene is also affected (Dymerska et al., 2017; Kempers et al.,
2011; Lynch et al., 2011; Perez-Cabornero et al., 2011). In theory,
this suggests that women with EPCAM-associated Lynch syndrome
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without deletions affectingMSH2 should be focused primarily on col-
orectal cancers and may not need to undergo aggressive surveillance
for endometrial cancer or prophylactic hysterectomy (Schmeler et al.,
2006). In practice, general screening guidelines remain conservative
and do not take the nuanced genetic difference into account.
Because EPCAM-associated Lynch syndrome is often caused by
silencing of an otherwise functional MSH2 gene, it is possible to envi-
sion that treatments that modify the MSH2 promoter hypermethyla-
tion or prevent the read-through transcription of EPCAM and MSH2
genes could preserve MSH2 function and could act as a cancer pre-
vention strategy. Such epigenetic approaches are being investigated
for use in chemotherapy. For example, 5-azacytidine (Aza) and Zebu-
larine are cytosine analogs that have been shown to cause reduced
DNAmethylation through degradation of a trapped drug-DNAmethy-
lase enzyme complex (Heerboth et al., 2014). Zebularine has been
used to reactivate the silenced and hypermethylated p16 tumor sup-
pressor in a murine model (Cheng et al., 2003). Additionally, anti-
sense targeting of the DNMT1 DNA methylase also can cause reex-
pression of a silenced p16 gene and has been used in the treatment
of an advanced renal cell carcinoma (Amato, 2007). Currently, DNA
methylation inhibitors are being developed for chemotherapy and not
for cancer suppression; careful analysis of any toxic side effects dur-
ing long-term administration would need to be evaluated against any
potential benefit in the suppression of tumor formation in Lynch syn-
drome caused by epigenetic silencing ofMSH2.
Lynch syndrome is a disease in which a personalized medicine
approach is feasible. Clinical history coupled with molecular tumor
screening of a patient's colon carcinoma can lead to genetic testing
and confirmation of Lynch syndrome in a patient and family mem-
bers. Understanding of genetics, EPCAM associated or not, can directly
inform the need for invasive and costly measures such as endome-
trial cancer screening and hysterectomy (Kempers et al., 2011). Fur-
ther studies are needed to assess the impact, practicality, and cost-
effectiveness of such approaches, given complex circumstances and
treatment strategies (Guglielmo, Staropoli, Giancotti, &Mauro, 2018).
8.3 EPCAM as a tumormarker and a cancer
therapy target
EpCAM, the tumor antigen first identified with monoclonal antibod-
ies (Herlyn et al., 1979), is expressed at high levels in many different
adenocarcinomas and squamous cell carcinomas (Fang et al., 2017;
Pan et al., 2018; Quak et al., 1990; Went et al., 2004), and has been
suggested to be a cancer stem cell marker (Imrich, Hachmeister, &
Gires, 2012). EpCAM has a role in promoting cell proliferation (Maet-
zel et al., 2009). EpCAM expression in a tumor is associated with
poor prognosis in breast, ovarian, esophageal, and gallbladder can-
cer (Spizzo et al., 2004; Spizzo et al., 2006; Stoecklein et al., 2006;
Trzpis et al., 2007; Varga et al., 2004) but is associated with some-
what improved prognosis in some colonic, gastric, and renal cancers
(Seligson et al., 2004; Songunet al., 2005;Went et al., 2005;Went et al.,
2006). EpCAM appears to promote cell proliferation in multiple stud-
ies involvingbothup- anddownregulationof expression (Chaves-Perez
et al., 2013;Maetzel et al., 2009;Munz et al., 2004;Wenqi et al., 2009),
which is due to the release of the intracellular C-terminal domain of
the protein (EplCD) by the tumor necrosis factor-𝛼-converting enzyme
and presenilin-2 proteases. The EplCD fragment becomes localized
to the nucleus and induces gene transcription effects that are onco-
genic in immunodeficient mice (Maetzel et al., 2009). Overexpression
of EpCAM has also been suggested to play a role in metastasis, due
to a role of EpCAM in disrupting cell adhesion and promoting cell
migration and cell invasion (Osta et al., 2004; Winter et al., 2003),
which is consistent experiments in rats demonstrating that overex-
pression promotes metastases (Wurfel et al., 1999). As a molecule
found at the surface of cancer cells, immunotherapies and antibody-
drug conjugates targeting EpCAM have been investigated for treat-
ing cancers (Baeuerle & Gires, 2007; Lund et al., 2014; Miller et al.,
2016; Moldenhauer et al., 2012), including catumaxomab, which has
been approved for the treatment of malignant ascites from epithe-
lial cancers (Linke, Klein, & Seimetz, 2010). Additionally, immunother-
apies targeting EpCAM might also function to reduce the formation
of metastases in some cancers of epithelial origin. Moreover, EpCAM
processing is also an EpCAM-related cancer therapy target based on
the fact that inhibition of the proteolysis inhibits growth signaling
(Maetzel et al., 2009), and screening in an experimental setting has
identified a number of potential inhibitors (Tretter et al., 2018). These
observations suggest that adjuvant treatments targeting EpCAM biol-
ogy may have the potential to broadly target epithelial tumors of dif-
ferent origins.
EpCAM's unique role in three disease states likely stems from its
multifaceted role in depending on the tissue of interest and EPCAM
variants and expression. Ongoing vigilance to report and correlate
variants to clinical outcomes is necessary to inform understanding of
disease progression and potential treatment strategies. Though the
last two decades have led to numerous novel insights, many further
studies are necessary to translate this knowledge to the bedside.
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